* Karyopharm Therapeutics Inc reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -30 cents. The mean expectation of seven analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -34 cents to -17 cents per share.

* Revenue rose 7.7% to $38.78 million from a year ago; analysts expected $37.79 million.

* Karyopharm Therapeutics Inc's reported EPS for the quarter was a loss of 26 cents​.

* The company reported a quarterly loss of $32.07 million.

* Karyopharm Therapeutics Inc shares had risen by 12.4% this quarter and gained 7.9% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

* In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $5.00 This summary was machine generated from LSEG data November 6 at 04:58 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.26 -0.26 Met

Jun. 30 2024 -0.30 0.15 Beat

Mar. 31 2024 -0.33 -0.32 Beat

Dec. 31 2023 -0.31 -0.36 Missed